Olaparib with or without bevacizumab for ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests whether taking the drug olaparib for one or two years, alone or with another drug called bevacizumab, can help keep ovarian cancer from coming back after initial chemotherapy and surgery. It is for people with certain genetic markers in their tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with stage III or IV ovarian, fallopian tube, or primary peritoneal cancer.
- Your tumor has a BRCA gene change or a high level of a DNA repair deficiency called HRD.
- You have already had surgery to remove as much cancer as possible and completed at least 4 cycles of platinum-based chemotherapy.
- Your cancer has not grown during or right after your first chemotherapy treatment.
- You have not taken a PARP inhibitor before (like olaparib, niraparib, or rucaparib).
- You are 18 or older and are in generally good health (able to do most daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two drug combinations (fluzoparib plus bevacizumab versus olaparib plus bevacizumab) given after initial chemotherapy to keep advanced ovarian cancer from coming back. Participants must have a specific genetic marker (HRD-positive) and have responded well to their first treatment.
This trial tests whether adding a drug that blocks blood vessel growth (angiogenesis inhibitor) to a PARP inhibitor works better than the PARP inhibitor alone for ovarian, fallopian-tube, or peritoneal cancers that have a specific DNA repair problem called HRD. It aims to find a more effective treatment for people with these cancers.
This trial tests whether taking two drugs, senaparib and bevacizumab, after initial chemotherapy can help keep advanced ovarian cancer from coming back. It is for patients whose tumors are homologous recombination proficient (HRP), meaning their cancer cells are better at repairing DNA, and who have responded well to their first platinum-based treatment.
This trial studies whether niraparib works better when combined with bevacizumab after chemotherapy and surgery for advanced ovarian, fallopian tube, or peritoneal cancer. If you qualify, you may help researchers find a treatment plan that controls the cancer for longer.
This trial tests whether adding fluzoparib to bevacizumab can help control ovarian cancer that has returned after earlier PARP inhibitor (PARPi) treatment. It may help shrink tumors or slow the cancer from growing again.
This trial tests whether niraparib, taken after surgery, works better when combined with bevacizumab in people with advanced ovarian, fallopian tube, or primary peritoneal cancer who have no visible tumor left. It also aims to see if this approach helps prevent the cancer from coming back.
Hear when a new Fallopian Tube Endometrioid Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.